IRIS
BASSET, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.437
AS - Asia 1.001
EU - Europa 935
SA - Sud America 149
AF - Africa 18
OC - Oceania 2
Totale 3.542
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.404
CN - Cina 432
IE - Irlanda 313
SG - Singapore 276
RU - Federazione Russa 147
HK - Hong Kong 138
DE - Germania 130
BR - Brasile 128
FI - Finlandia 101
IT - Italia 83
VN - Vietnam 49
GB - Regno Unito 39
IN - India 30
JP - Giappone 25
SE - Svezia 25
CA - Canada 19
PL - Polonia 16
ES - Italia 13
FR - Francia 13
ZA - Sudafrica 13
AT - Austria 11
BD - Bangladesh 11
MX - Messico 10
LT - Lituania 9
NL - Olanda 8
AR - Argentina 7
TR - Turchia 6
CZ - Repubblica Ceca 5
IQ - Iraq 5
BE - Belgio 4
CO - Colombia 4
AZ - Azerbaigian 3
BO - Bolivia 3
CL - Cile 3
GR - Grecia 3
ID - Indonesia 3
IR - Iran 3
PK - Pakistan 3
AL - Albania 2
AM - Armenia 2
AU - Australia 2
BG - Bulgaria 2
JO - Giordania 2
KR - Corea 2
LU - Lussemburgo 2
MU - Mauritius 2
PT - Portogallo 2
SA - Arabia Saudita 2
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DK - Danimarca 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
HN - Honduras 1
JM - Giamaica 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
MK - Macedonia 1
MY - Malesia 1
PE - Perù 1
PH - Filippine 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
TH - Thailandia 1
TM - Turkmenistan 1
UA - Ucraina 1
UY - Uruguay 1
VC - Saint Vincent e Grenadine 1
Totale 3.542
Salva come PNG Salva come JPEG
Città #
Dublin 311
Chandler 208
Dallas 182
Ashburn 157
Singapore 147
Hong Kong 137
Beijing 134
Helsinki 75
Los Angeles 61
Nanjing 54
Munich 49
Boardman 48
New York 41
Shanghai 36
Princeton 35
Lawrence 34
Medford 31
Ho Chi Minh City 26
Wilmington 26
Pavia 25
Tokyo 24
Nanchang 21
Moscow 20
Jacksonville 19
Redondo Beach 18
Buffalo 16
Changsha 16
Shenyang 15
Chicago 14
Hebei 14
São Paulo 14
Turku 14
Warsaw 14
Milan 13
Nuremberg 13
Piscataway 13
Tianjin 13
Johannesburg 12
Chennai 11
Denver 11
Hanoi 10
Jiaxing 10
Poplar 10
Stockholm 10
Falkenstein 9
San Francisco 9
Houston 8
London 8
Orem 8
Pune 8
Santa Clara 8
Seattle 8
Frankfurt am Main 7
Hangzhou 7
Montreal 7
Norwalk 7
Toronto 7
Vienna 7
Ankara 6
Atlanta 6
Brooklyn 6
Tamm 6
The Dalles 6
Woodbridge 6
Amsterdam 5
Fairfield 5
Hyderabad 5
Mexico City 5
Redwood City 5
Boston 4
Brasília 4
Brussels 4
Cagliari 4
Catania 4
Manchester 4
Phoenix 4
Rio de Janeiro 4
San Jose 4
Washington 4
Athens 3
Baku 3
Bexley 3
Brno 3
Charleston 3
Da Nang 3
Jinan 3
La Paz 3
Mülheim 3
Newark 3
Pouso Alegre 3
Vilnius 3
Vistarino 3
Amman 2
Annapolis 2
Baghdad 2
Belo Horizonte 2
Biên Hòa 2
Bogotá 2
Bollate 2
Casalecchio di Reno 2
Totale 2.426
Salva come PNG Salva come JPEG
Nome #
Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays 110
A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis 107
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 106
A patient with AL amyloidosis with negative free light chain results 105
Identification and quantification of urinary monoclonal proteins by capillary electrophoresis in AL amyloidosis 98
An N-glycosylation hotspot in immunoglobulin κ light chains is associated with AL amyloidosis 96
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis 96
Patterns of relapse after upfront bortezomib therapy in AL amyloidosis 93
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 92
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis 90
Prognostication of survival and progression to dialysis in AA amyloidosis 87
Severity and reversibility of cardiac dysfunction and residual concentration of amyloidogenic light chain predict overall survival of patients with AL amyloidosis who attain complete response 85
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies 85
The impact of renal function on the clinical performance of FLC measurement in AL amyloidosis 84
Urinary albumin to creatinine ratio in diagnosis and risk stratification of renal AL amyloidosis 83
Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome 79
A complicated evaluation of the response to the therapy in a patient with light chain deposition disease 78
Prospective urinary albumin/creatinine ratio for diagnosis, staging, and organ response assessment in renal AL amyloidosis: Results from a large cohort of patients 78
Bioelectrical impedance vector analysis-derived phase angle predicts survival in patients with systemic immunoglobulin light-chain amyloidosis 76
Daratumumab in light chain deposition disease: Rapid and profound hematologic response preserves kidney function 76
A case of monoclonal gammopathy of renal significance 75
High rate of profound clonal and renal responses with daratumumab treatment in heavily pre-treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate 73
Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome 72
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 71
Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis 71
Indicators of profound hematologic response in AL amyloidosis: complete response remains the goal of therapy 70
A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis 69
The lung in amyloidosis 69
Simple, reliable detection of amyloid in fat aspirates using the fluorescent dye FSB: Prospective study in 206 patients 69
Analysis of cyclin D1 mRNA expression levels in plasma cell dyscrasias: A systematic review of published literature 68
Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis 67
Growth Differentiation Factor 15 Is a New Biomarker for Survival and Renal Outcomes in Light Chain (AL) Amyloidosis 66
A biomarker-based approach in management of AL amyloidosis: from risk assessment to tailored-treatment strategy 63
Nonlymphoplasmacytic lymphomas associated with light-chain amyloidosis 62
Development and Validation of Staging Systems for AA Amyloidosis 58
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis 56
Clonal biomarkers for diagnosis and response to treatment assessment in light chain amyloidosis: The role of the laboratory 55
A safety review of drug treatments for patients with systemic immunoglobulin light chain (AL) amyloidosis 55
Protease-sensitive regions in amyloid light chains: what a common pattern of fragmentation across organs suggests about aggregation 55
A Strategy for the Selection of RT-qPCR Reference Genes Based on Publicly Available Transcriptomic Datasets 50
Sequential response-driven bortezomib-based therapy followed by autologous stem cell transplant in AL amyloidosis 50
Free light measurement identifies relapse and prompts to reconsider amyloid typing in a patient with AL amyloidosis 47
Delayed identification of monoclonal protein is associated with early death in isolated cardiac AL amyloidosis 46
Evaluation of response to treatment in a patient with light chain amyloidosis and low free light chain burden 42
Novel challenges in the management of immunoglobulin light chain amyloidosis: from the bench to the bedside 42
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients 41
Treatment of AL amyloidosis with bendamustine: A study of 122 patients 40
Early cardiac response is possible in stage IIIb cardiac AL amyloidosis and is associated with prolonged survival 36
null 30
null 29
Renal amyloidoses 26
Predictors of Early Death in Patients With Wild-Type Transthyretin Cardiac Amyloidosis 25
Daratumumab-based regimens versus CyBorD in newly diagnosed patients with AL amyloidosis and IIIb cardiac stage: A matched case-control study 24
Diagnostic Performance of the New Free Light Chain Ratio in Systemic Amyloidosis 21
Feasibility of a Biomarker-Based Screening for Pre-Symptomatic AL Amyloidosis in Patients With Intermediate/High-Risk MGUS 17
Left ventriculo-arterial coupling in a contemporary cohort of patients with wild-type transthyretin cardiac amyloidosis treated with tafamidis 13
Diffuse lung involvement as a rare presentation of systemic AL amyloidosis: a retrospective cohort study 11
null 6
Totale 3.644
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.369
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.369
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 5 3 17 25 2 0 2
2021/2022154 2 0 1 0 5 3 0 12 9 14 17 91
2022/2023698 59 62 11 31 46 56 13 35 351 3 21 10
2023/2024362 44 78 17 26 30 68 12 20 2 15 21 29
2024/2025864 27 57 9 28 10 75 79 35 210 50 107 177
2025/20261.198 147 149 193 308 319 82 0 0 0 0 0 0
Totale 3.644